Stocks Health care ABUS
NASDAQ · Health careArbutus Biopharma Corp (ABUS)
Arbutus Biopharma Corp brought in $181.7M of revenue over the twelve months to June 30, 2026, up 1,078.8% from a year earlier. Net income was $153.1M, a net margin of 84.2%. In fiscal 2025 capital spending exceeded operating cash flow by $39.6M. At June 30, 2026 it held $19.2M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 12, 2026.
What Arbutus Biopharma Corp does
Arbutus Biopharma Corp is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ABUS.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $14.1M | -$33.5M | -$0.17 | -$39.6M |
| 2024 | $6.2M | -$69.9M | -$0.38 | -$65M |
| 2023 | $18.1M | -$72.8M | -$0.44 | -$86.9M |
| 2022 | $39M | -$69.5M | -$0.46 | -$35.9M |
| 2021 | $11M | -$76.2M | -$0.83 | -$68.3M |
| 2020 | $6.9M | -$63.7M | -$1.00 | -$51.7M |
Latest SEC filings
What Arbutus Biopharma Corp has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 4, 2026Passive stake (5% or more) SCHEDULE 13G
- August 24, 2026Form SC TO-I filing SC TO-I
- August 21, 2026Form SC TO-C filing SC TO-C
- August 21, 2026Other event 8-K
- August 12, 2026Passive stake changed SCHEDULE 13G/A
- August 12, 2026Quarterly report 10-Q · period to June 30, 2026
- August 12, 2026
- July 16, 2026
- June 5, 2026
- May 27, 2026
Questions about ABUS
What does Arbutus Biopharma Corp do?
Arbutus Biopharma Corp is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ABUS.
Is Arbutus Biopharma Corp profitable?
Yes. Over the twelve months to June 30, 2026 it reported net income of $153.1M on revenue of $181.7M, a net margin of 84.2%.
How much revenue does Arbutus Biopharma Corp make?
Over the twelve months to June 30, 2026 Arbutus Biopharma Corp reported revenue of $181.7M. That is 1,078.8% more than a year earlier.
When did Arbutus Biopharma Corp last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 12, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 23, 2026.
Similar companies
Follow ABUS
Get an email when Arbutus Biopharma Corp files with the SEC: results, executive changes, material agreements and annual reports.
Follow ABUS: get an email when it filesWhere the numbers come from
Financial figures are the values Arbutus Biopharma Corp tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.